Read more

July 18, 2024
4 min watch
Save

VIDEO: Port delivery system maintains improvements in diabetic retinopathy at 2 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this Healio Video Perspective from the ASRS meeting, Margaret Chang, MD, MS, of Retinal Consultants Medical Group presents 2-year results for the port delivery system with ranibizumab.

The phase 3 Pavilion trial, involving 174 patients, investigated the platform for the treatment of nonproliferative diabetic retinopathy.

“PDS was able to maintain [Diabetic Retinopathy Severity Score] improvements achieved at year 1 through week 100 with 9-month refill intervals,” Chang said. “Patients who crossed over from the control group to PDS maintained or improved their DRSS score from baseline.”